Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Executive Deputy EditorIndividualAuthor
To the Editor: Part of the rationale for primary
stroke centers, which Dr Alberts and colleagues1
endorse, is to rapidly administer tPA to patients experiencing strokes. Alberts
discloses that he has financial ties to Genentech Inc, which manufactures
It would be reassuring if the authors could definitively state that
they have no other financial ties to any manufacturer of tPA. It would also
be important to state that no expenses of the Brain Attack Coalition have
been underwritten by any manufacturer of tPA.
Helmers SR. Issues in Establishing Primary Stroke Centers. JAMA. 2000;284(13):1647. doi:10.1001/jama.284.13.1647
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: